Deal Library / Pharma BD Deal Intelligence

Vaccines Deals

The Pharma Closeout tracks 11 deals, $31.0B in disclosed deal value, 6 with a post-close Outcome Score for Vaccines.

Median Critic Score: 73  ·  Median Outcome Score: 62

Best outcome: Crucell N.V. / Berna Biotech AG (85)  ·  Weakest outcome: Johnson & Johnson / Crucell N.V. (47)

All 11 deals

• Crucell N.V. / Berna Biotech AG — 2006 · $450M · Worked — the deal delivered on its rationale.
• Boehringer Ingelheim International GmbH / Sanofi SA (Merial Animal Health) — 2015 · $12.4B · Worked — the deal delivered on its rationale.
• Pfizer Inc. / Baxter International Inc. (commercial vaccines portfolio) — 2014 · $635M · Worked — the deal delivered on its rationale.
• GSK plc / Affinivax Inc. — 2022 · $3.3B · Mixed — partial payoff, real shortfalls.
• Novavax Inc. / Praha Vaccines — 2020 · $167M · Mixed — partial payoff, real shortfalls.
• Johnson & Johnson / Crucell N.V. — 2010 · $2.4B · Mixed — partial payoff, real shortfalls.
• Eli Lilly and Company / Curevo Vaccine, Inc. — 2026 · $1.5B
• Merck & Co. Inc. / Cidara Therapeutics, Inc. — 2025 · $9.2B
• Takeda Pharmaceutical Company Limited / Novavax Inc. — 2021 · $350M
• Novavax Inc. / SK Bioscience Co., Ltd. — 2021 · $300M
• Eli Lilly and Company / Shanghai Junshi Biosciences Co., Ltd. — 2020 · $255M

← Deal Library  ·  Interactive search  ·  How we score deals